{
    "ticker": "FCUV",
    "name": "Fulgent Genetics, Inc.",
    "description": "Fulgent Genetics, Inc. is a leading genomic testing company offering innovative solutions to improve patient outcomes through advanced genetic diagnostics. Founded in 2011, Fulgent specializes in providing comprehensive genetic testing services that aid in the diagnosis and treatment of various genetic disorders and diseases, including cancer, infectious diseases, and inherited conditions. The company utilizes state-of-the-art technology and a proprietary platform that enables the development of customized tests tailored to specific clinical needs. With a commitment to precision medicine, Fulgent's testing solutions empower healthcare providers to make data-driven decisions, enhancing patient care and treatment strategies. Fulgent's extensive test menu includes panels for hereditary cancer, infectious disease, and pharmacogenomics, among others. As the demand for genetic testing continues to grow, Fulgent remains at the forefront of the industry, expanding its offerings and enhancing its capabilities through continuous innovation. The company is dedicated to delivering high-quality results with fast turnaround times while maintaining rigorous standards of accuracy and reliability. Fulgent Genetics is poised to play a crucial role in the evolving landscape of personalized medicine and the future of healthcare.",
    "industry": [
        "Healthcare",
        "Genomics"
    ],
    "headquarters": "Temple City, California, USA",
    "founded": "2011",
    "website": "https://www.fulgentgenetics.com",
    "ceo": "Minh T. Nguyen",
    "social_media": {
        "twitter": "https://twitter.com/FulgentGenetics",
        "linkedin": "https://www.linkedin.com/company/fulgent-genetics/"
    },
    "investor_relations": "https://investors.fulgentgenetics.com",
    "key_executives": [
        {
            "name": "Minh T. Nguyen",
            "position": "CEO"
        },
        {
            "name": "Thomas E. Burnett",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Genetic Testing",
            "products": [
                "Hereditary Cancer Testing",
                "Infectious Disease Testing",
                "Pharmacogenomics Testing"
            ]
        }
    ],
    "seo": {
        "meta_title": "Fulgent Genetics, Inc. | Leading Provider of Genetic Testing Solutions",
        "meta_description": "Explore Fulgent Genetics, Inc., a leader in genomic testing that provides innovative solutions for genetic diagnostics. Learn about our services and commitment to precision medicine.",
        "keywords": [
            "Fulgent Genetics",
            "Genetic Testing",
            "Genomics",
            "Precision Medicine",
            "Hereditary Cancer Testing",
            "Infectious Disease Testing"
        ]
    },
    "faq": [
        {
            "question": "What does Fulgent Genetics specialize in?",
            "answer": "Fulgent Genetics specializes in genomic testing and offers a range of tests for hereditary cancer, infectious diseases, and pharmacogenomics."
        },
        {
            "question": "Who is the CEO of Fulgent Genetics?",
            "answer": "Minh T. Nguyen is the CEO of Fulgent Genetics, Inc."
        },
        {
            "question": "Where is Fulgent Genetics headquartered?",
            "answer": "Fulgent Genetics is headquartered in Temple City, California, USA."
        },
        {
            "question": "What types of tests does Fulgent offer?",
            "answer": "Fulgent offers tests for hereditary cancer, infectious diseases, and pharmacogenomics, among others."
        },
        {
            "question": "When was Fulgent Genetics founded?",
            "answer": "Fulgent Genetics was founded in 2011."
        }
    ],
    "competitors": [
        "NTRA",
        "ILMN",
        "CDNA",
        "EXAS"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "REGN"
    ]
}